Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced ms mouse model

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhang, Lin ^a   Yu, Wu ^a   Schroedter, Ingo ^b   Kong, Jiming ^a   Vrontakis, Maria ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CUPRIZONE; GALANIN; GALANIN RECEPTOR 1; GALANIN RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; MONOAMINE OXIDASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BODY WEIGHT; CELL DEATH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEMYELINATION; FEMALE; GENE OVEREXPRESSION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REMYELINIZATION; STEM CELL; TRANSGENIC MOUSE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY;

MUS; MUS MUSCULUS;

ANIMALS; CUPRIZONE; DISEASE MODELS, ANIMAL; GALANIN; MICE; MICE, TRANSGENIC; MONOAMINE OXIDASE INHIBITORS; MULTIPLE SCLEROSIS; OLIGODENDROGLIA;

EID: 84863376198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033901     Document Type: Article

References (42)

1. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, et al. (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122 (Pt 12): 2279-2295.
2. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES, (1993) Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33: 137-151.
3. Blakemore WF, Keirstead HS, (1999) The origin of remyelinating cells in the central nervous system. J Neuroimmunol 98: 69-76.
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, et al. (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128: 2705-2712.
5. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, et al. (1999) Cortical lesions in multiple sclerosis. Brain 122 (Pt 1): 17-26.
6. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ, (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9: 323-331.
7. La Mantia L, Munari LM, Lovati R, (2010) Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev pp. CD004678.
8. Zhang J, Kramer EG, Mahase S, Dutta DJ, Bonnamain V, et al. (2011) Targeting oligodendrocyte protection and remyelination in multiple sclerosis. Mt Sinai J Med 78: 244-257.
9. Vrontakis ME, (2002) Galanin: a biologically active peptide. Curr Drug Targets CNS Neurol Disord 1: 531-541.
10. Lang R, Gundlach AL, Kofler B, (2007) The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115: 177-207.
11. Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, et al. (2008) Galanin acts as a trophic factor to the central and peripheral nervous systems. Cell Mol Life Sci 65: 1806-1812.
12. Shen PJ, Larm JA, Gundlach AL, (2003) Expression and plasticity of galanin systems in cortical neurons, oligodendrocyte progenitors and proliferative zones in normal brain and after spreading depression. Eur J Neurosci 18: 1362-1376.
13. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, et al. (2004) Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci U S A 101: 5105-5110.
14. Mazarati A, Lu X, Shinmei S, Badie-Mahdavi H, Bartfai T, (2004) Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 128: 431-441.
15. Shen PJ, Yuan CG, Ma J, Cheng S, Yao M, et al. (2005) Galanin in neuro(glio)genesis: expression of galanin and receptors by progenitor cells in vivo and in vitro and effects of galanin on neurosphere proliferation. Neuropeptides 39: 201-205.
16. Jungnickel SR, Yao M, Shen PJ, Gundlach AL, (2005) Induction of galanin receptor-1 (GalR1) expression in external granule cell layer of post-natal mouse cerebellum. J Neurochem 92: 1452-1462.
17. Mazarati A, Lu X, Kilk K, Langel U, Wasterlain C, et al. (2004) Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 19: 3235-3244.
18. Ubink R, Calza L, Hokfelt T, (2003) 'Neuro'-peptides in glia: focus on NPY and galanin. Trends Neurosci 26: 604-609.
19. Wraith DC, Pope R, Butzkueven H, Holder H, Vanderplank P, et al. (2009) A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci U S A 106: 15466-15471.
20. Matsushima GK, Morell P, (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11: 107-116.
21. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717.
22. Perumal P, Vrontakis ME, (2003) Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone. J Endocrinol 179: 145-154.
23. Poritsanos NJ, Mizuno TM, Lautatzis ME, Vrontakis M, (2009) Chronic increase of circulating galanin levels induces obesity and marked alterations in lipid metabolism similar to metabolic syndrome. Int J Obes (Lond) 33: 1381-1389.
24. Torkildsen O, Brunborg LA, Myhr KM, Bo L, (2008) The cuprizone model for demyelination. Acta Neurol Scand Suppl 188: 72-76.
25. Broadwell RD, Sofroniew MV, (1993) Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120: 245-263.
26. Begley DJ, (1994) Peptides and the blood-brain barrier: the status of our understanding. Ann N Y Acad Sci 739: 89-100.
27. Murck H, Held K, Ziegenbein M, Kunzel H, Holsboer F, et al. (2004) Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology 29: 1205-1211.
28. Simons M, Trotter J, (2007) Wrapping it up: the cell biology of myelination. Curr Opin Neurobiol 17: 533-540.
29. Chekhonin VP, Gurina OI, Dmitrieva TB, Semenova AV, Savchenko EA, et al. (2000) [Myelin basic protein. Structure, properties, function and role in diagnosing demyelinating diseases]. Vopr Med Khim 46: 549-563.
30. Tansey FA, Cammer W, (1991) A pi form of glutathione-S-transferase is a myelin- and oligodendrocyte-associated enzyme in mouse brain. J Neurochem 57: 95-102.
31. Zhang Y, Xu H, Jiang W, Xiao L, Yan B, et al. (2008) Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res 106: 182-191.
32. Miron VE, Kuhlmann T, Antel JP, (2011) Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim Biophys Acta 1812: 184-193.
33. Barnett MH, Prineas JW, (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458-468.
34. Gregg C, (2009) Pregnancy, prolactin and white matter regeneration. J Neurol Sci 285: 22-27.
35. Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, et al. (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 27: 1812-1823.
36. Isgaard J, Aberg D, Nilsson M, (2007) Protective and regenerative effects of the GH/IGF-I axis on the brain. Minerva Endocrinol 32: 103-113.
37. Aberg D, (2010) Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis. Endocr Dev 17: 63-76.
38. McMahon EJ, Suzuki K, Matsushima GK, (2002) Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 130: 32-45.
39. Branchek TA, Smith KE, Gerald C, Walker MW, (2000) Galanin receptor subtypes. Trends Pharmacol Sci 21: 109-117.
40. Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, et al. (2004) Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A 101: 10470-10475.
41. Vrontakis ME, Schroedter IC, Cosby H, Friesen HG, (1992) Expression and secretion of galanin during pregnancy in the rat. Endocrinology 130: 458-464.
42. National Institutes of Health Image J website. Image J user guide. Available: http://rsbweb.nih.gov/ij/docs/user-guide.pdf. Accessed 2011 May 01.